ENFN Stock Price, Enfusion, Inc. Quote, Chart

Market Summary

USD9.67+0.03

Market Closed

0.31%

ENFN Alerts

Big fall in earnings (Y/Y)

Losses in recent quarter

ENFN Stock Price

View Fullscreen

ENFN RSI Chart

ENFN Valuation

Market Cap

865.6M

Price/Earnings (Trailing)

340.63

Price/Sales (Trailing)

4.77

EV/EBITDA

51.06

Price/Free Cashflow

36.51

ENFN Price/Sales (Trailing)

ENFN Profitability

Operating Margin

66.68%

EBT Margin

3.04%

Return on Equity

3.08%

Return on Assets

2.29%

Free Cashflow Yield

2.74%

ENFN Fundamentals

ENFN Revenue

Revenue (TTM)

181.6M

Rev. Growth (Yr)

17.28%

Rev. Growth (Qtr)

3.37%

ENFN Earnings

Earnings (TTM)

2.5M

Earnings Growth (Yr)

-118.3%

Earnings Growth (Qtr)

-186.52%

Breaking Down ENFN Revenue

Last 7 days

6.9%

Last 30 days

4.0%

Last 90 days

6.5%

Trailing 12 Months

25.8%

How does ENFN drawdown profile look like?

ENFN Financial Health

Current Ratio

4.07

ENFN Investor Care

Shares Dilution (1Y)

0.73%

Diluted EPS (TTM)

0.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	181.6M	0	0	0
2023	157.2M	163.4M	168.6M	174.5M
2022	121.5M	131.6M	141.7M	150.3M
2021	87.6M	95.6M	103.7M	111.7M
2020	0	0	0	79.6M
2019	0	0	0	59.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Enfusion, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 05, 2024	movchan oleg	acquired	-	-	249,701	chief executive officer
Mar 01, 2024	gutowski valeria	sold (taxes)	-9,112	8.67	-1,051	chief accounting officer
Mar 01, 2024	bastone bronwen	acquired	45,162	0.411267	109,812	chief people officer
Mar 01, 2024	herring bradley	acquired	82,763	0.966066	85,671	chief financial officer
Mar 01, 2024	gutowski valeria	acquired	26,322	1.29423	20,338	chief accounting officer
Mar 01, 2024	herring bradley	sold (taxes)	-20,157	8.67	-2,325	chief financial officer
Mar 01, 2024	movchan oleg	sold (taxes)	-35,278	8.67	-4,069	chief executive officer
Mar 01, 2024	movchan oleg	acquired	120,400	8.67	13,887	chief executive officer
Mar 01, 2024	campobasso matthew	acquired	27,085	1.03406	26,193	general counsel
Mar 01, 2024	pawar neal	acquired	-	-	144,176	chief operating officer

Which funds bought or sold ENFN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	10.96	18,293	333,019	-%
May 16, 2024	JANE STREET GROUP, LLC	added	115	180,272	351,574	-%
May 15, 2024	Gotham Asset Management, LLC	new	-	94,082	94,082	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	added	56.25	174,535	530,700	-%
May 15, 2024	JANUS HENDERSON GROUP PLC	reduced	-1.18	-914,644	14,952,200	0.01%
May 15, 2024	Voya Investment Management LLC	reduced	-18.02	-32,915	117,891	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	73.79	203,961	514,254	-%
May 15, 2024	CITADEL ADVISORS LLC	added	420	4,758,040	5,958,520	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	0.38	-22,501	503,385	-%
May 15, 2024	Royal Bank of Canada	reduced	-80.15	-89,000	20,000	-%

Are Funds Buying or Selling ENFN?

Are funds buying ENFN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ENFN

No. of Funds

Unveiling Enfusion, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	brown capital management llc	14.03%	11,817,661	SC 13G/A
Feb 14, 2024	csl tech holdings llc	13.6%	13,768,183	SC 13G/A
Feb 14, 2024	werner capital llc	5.04%	4,682,016	SC 13G/A
Feb 14, 2024	iconiq strategic partners v, l.p.	8.8%	7,748,000	SC 13G/A
Feb 14, 2024	dragoneer investment group, llc	0%	0	SC 13G/A
Feb 07, 2024	lra ventures, llc	8.46%	7,972,007	SC 13G/A
Jan 19, 2024	malherbe investments llc	10.06%	9,870,386	SC 13G/A
Jun 23, 2023	ftv iv, l.p.	1.48%	31,297,606	SC 13D
Mar 09, 2023	brown capital management llc	10.50%	7,244,171	SC 13G/A
Feb 14, 2023	brown capital management llc	8.70%	6,001,842	SC 13G/A

Recent SEC filings of Enfusion, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 19, 2024	8-K	Current Report
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	S-8	Employee Benefits Plan
Mar 07, 2024	4	Insider Trading

Peers (Alternatives to Enfusion, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
CRM	277.0B	34.9B	3.35%	33.87%	66.98	7.95	11.18%	1888.46%
UBER	137.2B	38.6B	-8.72%	67.31%	98.72	3.56	14.01%	141.26%
ADSK	47.3B	5.3B	2.96%	8.03%	51.62	8.85	9.15%	48.14%
ANSS	28.6B	2.2B	0.65%	6.79%	65.84	12.85	3.59%	-21.47%
ZM	19.3B	4.5B	8.62%	-7.71%	30.27	4.26	3.06%	514.65%
MID-CAP
APPF	8.7B	671.8M	11.01%	66.39%	113.53	12.92	33.64%	185.98%
LYFT	6.7B	4.7B	-3.99%	99.28%	-36.23	1.43	10.90%	88.31%
ALRM	3.5B	895.2M	7.46%	35.00%	38.7	3.87	5.72%	46.94%
AYX	3.4B	970.0M	0.90%	-15.87%	-19.13	3.53	13.46%	43.89%
AI	3.2B	296.4M	28.11%	-1.60%	-11.7	10.73	11.14%	-3.59%
AGYS	2.7B	228.1M	21.43%	43.87%	31.34	11.99	18.99%	599.09%
SMALL-CAP
AVID	1.2B	413.5M	0.63%	-1.64%	92.02	2.88	-1.65%	-71.35%
AEYE	256.1M	31.6M	76.57%	260.07%	-43.61	8.1	2.76%	43.72%
APPS	253.0M	572.4M	33.33%	-82.31%	-1.28	0.44	-19.38%	-489.49%
ASUR	193.1M	117.7M	5.95%	-44.01%	-19.58	1.64	12.54%	11.24%

Enfusion, Inc. News

Latest updates

Enfusion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Revenue	3.4%	48,052	46,486	44,357	42,721	40,971	40,517	39,151	36,540	34,141	31,853	29,045	26,449	24,353	-	-
Cost Of Revenue	3.5%	16,174	15,624	14,507	14,208	13,302	13,296	11,974	10,847	10,983	10,164	8,095	6,777	6,809	-	-
Gross Profit	3.3%	31,878	30,862	29,850	28,513	27,669	27,221	27,177	25,693	23,158	21,689	20,950	19,672	17,544	-	-
Operating Expenses	14.8%	32,991	28,728	27,161	26,067	22,990	25,849	24,236	29,599	35,529	314,188	16,047	13,762	11,741	-	-
S&GA Expenses	12.0%	6,217	5,552	5,503	5,277	4,086	6,001	7,278	7,575	8,432	39,402	4,901	4,264	3,158	-	-
EBITDA Margin	-27.0%	0.09*	0.12*	0.11*	0.11*	0.08*	-0.04*	-2.12*	-2.28*	-2.39*	-2.44*	0.08*	0.09*	0.09*	0.10*	0.25*
Interest Expenses	-	-	-	-	-	-	-	4.00	1.00	6.00	526	1,485	1,410	1,392	-	-
Income Taxes	-109.1%	-117	1,280	367	188	396	418	287	219	150	-125	154	249	302	-	-
Earnings Before Taxes	-140.3%	-878	2,180	3,028	1,186	5,090	1,206	2,885	-3,906	-12,374	-294,020	3,447	4,500	4,411	-	-
EBT Margin	-53.8%	0.03*	0.07*	0.06*	0.06*	0.03*	-0.08*	-2.17*	-2.33*	-2.46*	-2.52*	0.04*	0.05*	0.05*	0.06*	0.22*
Net Income	-186.5%	-539	623	1,828	629	2,945	494	1,539	-2,422	-7,265	-169,969	3,293	4,251	4,109	-	-
Net Income Margin	-59.5%	0.01*	0.03*	0.03*	0.03*	0.02*	-0.05*	-1.26*	-1.34*	-1.40*	-1.42*	0.04*	0.04*	0.05*	0.05*	0.21*
Free Cashflow	-90.6%	898	9,509	9,499	3,799	-1,626	9,721	6,920	798	-7,268	-5,535	-4,281	4,987	-1,585	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q3	2021Q2	2020Q4
Assets	1.8%	111	109	102	94.00	121	124	116	110	105	106	89.00	73.00	56.00	39.00
Current Assets	1.5%	71.00	70.00	62.00	60.00	87.00	97.00	96.00	90.00	86.00	90.00	36.00	-	-	29.00
Cash Equivalents	-7.6%	33.00	36.00	32.00	28.00	55.00	63.00	64.00	57.00	56.00	64.00	8.00	-	0.00	14.00
Net PPE	2.9%	19.00	18.00	18.00	18.00	17.00	16.00	15.00	16.00	15.00	13.00	12.00	-	-	9.00
Liabilities	-10.0%	28.00	31.00	28.00	22.00	22.00	20.00	12.00	10.00	8.00	9.00	109	-	-	107
Current Liabilities	-14.3%	17.00	20.00	16.00	14.00	14.00	17.00	12.00	10.00	8.00	8.00	16.00	-	-	11.00
Shareholder's Equity	54.0%	83.00	54.00	51.00	72.00	99.00	65.00	103	100	97.00	97.00	0.00	-	0.00	-233
Retained Earnings	-0.3%	-173	-172	-173	-175	-176	-178	-179	-180	-178	-171	-	-	-	-
Additional Paid-In Capital	2.2%	232	227	225	224	240	244	241	241	234	227	-	-	-	-
Shares Outstanding	1.5%	90.00	88.00	88.00	88.00	89.00	85.00	85.00	84.00	83.00	83.00	-	-	-	-
Minority Interest	3.2%	25.00	24.00	23.00	24.00	35.00	38.00	42.00	41.00	42.00	42.00	-	-	-	-
Float	-	-	-	-	438	-	-	-	258	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-76.7%	1,533	6,586	12,106	6,018	924	7,521	7,842	2,890	-4,097	-5,812	-2,309	7,036	767	-	-	-
Share Based Compensation	105.7%	7,001	3,404	2,623	2,578	-1,147	4,205	438	7,668	12,682	-	-	-	-	-	-	-
Cashflow From Investing	-19.7%	-2,748	-2,295	-2,607	-2,219	-2,550	-1,746	-922	-2,092	-3,171	-1,641	-1,972	-2,049	-2,352	-	-	-
Cashflow From Financing	-137.1%	-1,373	-579	-5,309	-30,842	-6,353	-7,042	-20.00	-92.00	-805	63,382	-1,788	-2,581	-164	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ENFN Income Statement

2024-03-31

Condensed Consolidated Interim Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES:
Total revenues	$ 48,052	$ 40,971
COST OF REVENUES:
Total cost of revenues	16,174	13,302
Gross profit	31,878	27,669
OPERATING EXPENSES:
General and administrative	20,223	14,473
Sales and marketing	6,217	4,086
Technology and development	6,551	4,431
Total operating expenses	32,991	22,990
(Loss) income from operations	(1,113)	4,679
NON-OPERATING INCOME (EXPENSE):
Interest income, net	317	492
Other expense, net	(82)	(81)
Total non-operating income (expense)	235	411
(Loss) income before income taxes	(878)	5,090
Income taxes	(117)	396
Net (loss) income	(761)	4,694
Net (loss) income attributable to non-controlling interests	(222)	1,749
Net (loss) income attributable to Enfusion, Inc.	$ (539)	$ 2,945
Net (loss) income per Class A common shares attributable to Enfusion, Inc.:
Basic	$ (0.01)	$ 0.04
Diluted	$ (0.01)	$ 0.04
Weighted-average number of Class A common shares outstanding:
Basic	89,509	88,863
Diluted	89,509	132,346
Platform subscriptions
REVENUES:
Total revenues	$ 44,689	$ 37,998
COST OF REVENUES:
Total cost of revenues	14,394	11,675
Managed services
REVENUES:
Total revenues	3,177	2,744
COST OF REVENUES:
Total cost of revenues	1,697	1,564
Other
REVENUES:
Total revenues	186	229
COST OF REVENUES:
Total cost of revenues	$ 83	$ 63

ENFN Balance Sheet

2024-03-31

Condensed Consolidated Interim Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 32,894	$ 35,604
Accounts receivable, net	30,932	28,069
Prepaid expenses	5,420	5,009
Other current assets	1,677	1,170
Total current assets	70,923	69,852
Property, equipment, and software, net	18,851	18,314
Right-of-use-assets, net	14,151	14,304
Other assets	7,038	6,502
Total assets	110,963	108,972
Current liabilities:
Accounts payable	3,364	2,212
Accrued expenses and other current liabilities	9,513	13,841
Current portion of lease liabilities	4,529	4,256
Total current liabilities	17,406	20,309
Lease liabilities, net of current portion	10,931	11,181
Total liabilities	28,337	31,490
Commitment and contingencies (Note 7)
Stockholders' Equity:
Preferred stock, $0.001 par value; 100,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Additional paid-in capital	231,881	226,877
Accumulated deficit	(173,471)	(172,932)
Accumulated other comprehensive loss	(484)	(406)
Total stockholders' equity attributable to Enfusion, Inc.	58,054	53,666
Non-controlling interests	24,572	23,816
Total stockholders' equity	82,626	77,482
Total liabilities and stockholders' equity	110,963	108,972
Common Class A
Stockholders' Equity:
Common stock	90	88
Common Class B
Stockholders' Equity:
Common stock	$ 38	$ 39

About Enfusion, Inc.

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. The company was founded in 1997 and is headquartered in Chicago, Illinois.

CEO	Mr. Oleg Movchan
WEBSITE	enfusion.com
INDUSTRY	Software - Apps
EMPLOYEES	1006

Enfusion, Inc. Frequently Asked Questions

What is the ticker symbol for Enfusion, Inc.? What does ENFN stand for in stocks?

ENFN is the stock ticker symbol of Enfusion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Enfusion, Inc. (ENFN)?

As of Fri May 17 2024, market cap of Enfusion, Inc. is 865.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ENFN stock?

You can check ENFN's fair value in chart for subscribers.

What is the fair value of ENFN stock?

You can check ENFN's fair value in chart for subscribers. The fair value of Enfusion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Enfusion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ENFN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Enfusion, Inc. a good stock to buy?

The fair value guage provides a quick view whether ENFN is over valued or under valued. Whether Enfusion, Inc. is cheap or expensive depends on the assumptions which impact Enfusion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENFN.

What is Enfusion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ENFN's PE ratio (Price to Earnings) is 340.63 and Price to Sales (PS) ratio is 4.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENFN PE ratio will change depending on the future growth rate expectations of investors.